All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

What is BloodFlow and how can it improve MRD assessment in MM?

Featured
Jan 6, 2023
Share:
Learning objective: After reading this article, learners will be able to cite a new development in the monitoring of multiple myeloma.

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Bruno Paiva, University of Navarra, Pamplona, ES. We asked, What is BloodFlow and how can it improve minimal residual disease (MRD) assessment in multiple myeloma?

What is BloodFlow and how can it improve MRD assessment in MM?

Paiva opens by highlighting MRD detection continuous monitoring as an unmet need for patients with multiple myeloma. BloodFlow is then outlined as a newly developed flow cytometry method to detect MRD in blood with a greater sensitivity than next-generation flow (NGF). Paiva describes how BloodFlow works using immunomagnetic enrichment of circulating plasma cells prior to NGF, as well as the range of its sensitivity (up to 10−8). The answer is closed by looking to the future of MRD assessment, including the possibility of combining different minimally invasive techniques to improve its prognostic value.